Emergence Therapeutics raises €87 million Series A financing
Lead product is a next-generation Nectin-4 ADC designed to increase efficacy and minimize toxicity
08-Dec-2021 -
Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, announces that it has closed an €87 million series A financing round.
The round was led by Pontifax Venture Capital and includes RA Capital ...
antibody-drug conjugate
bladder cancer
breast cancer
+5